Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
- 11 January 2024
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 143 (2) , 178-182
Abstract
Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.Keywords
This publication has 12 references indexed in Scilit:
- Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysisTherapies, 2022
- A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosisJournal of the American Academy of Dermatology, 2022
- Second primary malignancy in myelofibrosis patients treated with ruxolitinibBritish Journal of Haematology, 2020
- Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and NeckJAMA Otolaryngology–Head & Neck Surgery, 2020
- Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patientsBlood Advances, 2019
- Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinibJAAD Case Reports, 2018
- Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific DeathJAMA Dermatology, 2016
- Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2013
- The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factorsJournal of Surgical Oncology, 2012
- Clinical course of malignancies in renal transplant recipientsCancer, 1993